Hoth Therapeutics

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hoth Therapeutics Inc (NASDAQ: HOTH) shares were roaring higher Monday after the biopharma announced its foray into COVID-19 vaccine development, joining a host of companies engaged in research for a preventative treatment for the pandemic.

Hoth Therapeutics Shares Jump On COVID-19 Vaccine Development Plans

ORLANDO, Fla., Jan.  17, 2020  (GLOBE NEWSWIRE) -- It doesn’t take an analyst to suggest that high value merger and acquisition activity in any industry is a bullish sign. And it assuredly doesn’t take any research firm at all to suggest that an eczema related company like Hoth Therapeutics, Inc. (NASDAQ: HOTH) would be pleased to see none other than Eli Lilly acquire eczema company Dermira  for a whopping $1.1 billion  all cash deal.

Emerging Markets Report:  A Very Big Deal

ORLANDO, Fla., Jan.  14, 2020  (GLOBE NEWSWIRE) -- The headline of our written offering today probably appears a little different from our regular titles. Typically we don’t lead with things that are so widely despised or feared. But when we are discussing biopharmaceutical company Hoth Therapeutics, Inc. (NASDAQ: HOTH) the widespread loathing of the aforementioned maladies is precisely the point.

Emerging Markets Report: Acne, Eczema, and Asthma

ORLANDO, Fla., Dec.  23, 2019  (GLOBE NEWSWIRE) -- As the holidays roll into November and December many companies go quietly into the New Year, eschewing news releases or large scale investor communication. That has definitely not been the case for Hoth Therapeutics, Inc. (NASDAQ: HOTH) - a biopharmaceutical company focused on developing new generation therapies for a wide variety of dermatological disorders.

Emerging Markets Report: A Pretty Good Month

News for Hoth Therapeutics Stock (HOTH)